30 completed, 12 active not recruiting, 12 terminated, 2 withdrawn. 31 Phase 2, 29 Phase 1, 2 Early Phase 1.
Follow adavosertib: new trials by email Literature Review of adavosertib trials Research Report on adavosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adavosertib and Gemcitabine in Advanced Pancreatic Adavosertib, Gemcitabine - Pancreatic Cancer | Phase 2 | Withdrawn | James Cleary, MD, PhD | 2022-06-01 | 2022-06-14 | |
| Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib [14C]Adavosertib - Advanced Solid Tumors | Phase 1 | Terminated | AstraZeneca | 2 | 2021-10-01 | 2022-09-06 |
| A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours Adavosertib - Advanced Solid Tumours | Phase 1 | Terminated | AstraZeneca | 3 | 2021-09-13 | 2022-09-02 |
| A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib Adavosertib, Itraconazole, Rifampicin - Advanced Solid Tumours | Phase 1 | Terminated | AstraZeneca | 5 | 2021-06-28 | 2022-09-16 |
| Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers Adavosertib, Radiation Therapy - Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 4 | 2021-04-09 | 2026-07-31 |
| A Study of Adavosertib as Treatment for Uterine Serous Carcinoma Adavosertib - Uterine Serous Carcinoma | Phase 2 | Completed | AstraZeneca | 109 | 2020-11-30 | 2023-08-14 |
| Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study Adavosertib, Olaparib - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2020-06-30 | 2026-09-30 |
| Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours Adavosertib (AZD1775) - Advanced Solid Tumours | Phase 1 | Completed | AstraZeneca | 6 | 2020-06-24 | 2022-07-25 |
| Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 Adavosertib - Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 18 | 2019-01-29 | 2026-10-23 |
| AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification Adavosertib - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 31 | 2019-01-16 | 2023-10-17 |
| Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Adavosertib, Olaparib, Ceralasertib - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 96 | 2018-12-07 | 2026-07-16 |
| AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma AZD1775 - Uterine Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 49 | 2018-10-22 | 2026-09-28 |
| Prostate Cancer Biomarker Enrichment and Treatment Selection Adavosertib, Savolitinib, Darolutamide - Prostate Cancer | Phase 2 | Active not recruiting | Canadian Cancer Trials Group | 200 | 2018-08-01 | 2025-08-21 |
| Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers Adavosertib, Cisplatin, External Beam Radiation Therapy - Cervical Carcinoma, Endometrioid Adenocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 10 | 2018-05-29 | 2024-02-20 |
| To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle). - Metastatic Triple Negative Breast Cancer | Phase 2 | Active not recruiting | AstraZeneca | 273 | 2018-03-07 | 2026-10-14 |
| WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer AZD1775, Cisplatin, Radiotherapy - Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma | Phase 1 | Completed | University of Birmingham | 9 | 2017-06-22 | 2024-09-19 |
| Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia Cytarabine, Filgrastim, Fludarabine Phosphate - CNS 2a, CNS 2b | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2017-05-25 | 2017-05-03 | |
| WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q) | Phase 2 | Completed | Mayo Clinic | 3 | 2017-05-05 | 2019-09-06 |
| Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) Adavosertib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 33 | 2017-03-24 | 2026-11-03 |
| CISPLATIN + AZD-1775 In Breast Cancer Cisplatin, AZD1775 - Triple-negative Metastatic Breast Cancer | Phase 2 | Completed | Dana-Farber Cancer Institute | 34 | 2017-01-18 | 2021-11-23 |
Showing 20 of 57. Sign in to see all of them.
Ovarian Neoplasms (6) · Small Cell Lung Carcinoma (4) · Squamous Cell Carcinoma of Head and Neck (4) · Fallopian Tube Neoplasms (3) · Glioblastoma (3) · Leukemia, Myeloid, Acute (3) · Lung Neoplasms (3) · Neoplasms (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2) · Hematologic Neoplasms (2) · Lymphoma (2) · Multiple Myeloma (2)
National Cancer Institute (NCI) (17) · AstraZeneca (16) · Merck Sharp & Dohme LLC (4) · Samsung Medical Center (3) · Dana-Farber Cancer Institute (2) · M.D. Anderson Cancer Center (2) · Canadian Cancer Trials Group (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · James Cleary, MD, PhD (1) · Joseph Paul Eder (1) · Mayo Clinic (1) · NYU Langone Health (1) · St. Joseph's Hospital and Medical Center, Phoenix (1) · The Netherlands Cancer Institute (1)
United States (39) · Canada (12) · Spain (6) · United Kingdom (6) · South Korea (5) · France (4) · Netherlands (4) · Italy (3) · Germany (2) · Japan (2) · Poland (2) · Australia (1) · Belgium (1) · Czechia (1) · Denmark (1)
David R Spigel, MD (2) · A P Chen (1) · Aaron Hansen (1) · Amit M Oza (1) · Andrew Tutt, MB ChB PhD (1) · Birgit Geoerger, MD (1) · Danielle A Shafer (1) · Deirdre Cohen, MD (1) · Dr Toshihiko Doi, MD (1) · Dr. Jason Lickliter, MD (1) · Dr. Noboru Yamamoto, MD (1) · Dr. Paul De Souza, MD (1) · Eduardo Mendez (1) · Eric D Miller (1)
PMID 32203306, PMID 41212474, PMID 25964244, PMID 26586415, PMID 26602013, PMID 27601554, PMID 27998224, PMID 29798906, PMID 31398082, PMID 31538815, PMID 32379297, PMID 32463741, PMID 33048619, PMID 33485453, PMID 33705205, PMID 33892407, PMID 34347542, PMID 34543871, PMID 34645648, PMID 34716177, PMID 34904813, PMID 35133871, PMID 35138919, PMID 35292802, PMID 36351402, PMID 36469840, PMID 37053535, PMID 37236033, PMID 37278879, PMID 37322121, PMID 37934000, PMID 38591867, PMID 38593512, PMID 38920407, PMID 39487373, PMID 39560862, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40262070, PMID 40865033, PMID 41066729, PMID 41838385, PMID 42686334
2015 (3), U10CA180820 (3), UM1CA097452 (3), UM1CA186644 (3), 2016 (2), N01CM00032 (2), U24CA196172 (2), UM1CA186688 (2), 2009 (1), 2017 (1), N01CM00038 (1), N01CM00071 (1), N01CM00100 (1), P30CA015083 (1), P30CA015704 (1)